Introduction
The IRS has issued substantial changes regarding how taxpayers must treat research and experimental (R&E) or specified R&E (“SRE”) expenditures under § 174 and the related accounting method rules. These changes affect all businesses incurring R&E costs, whether domestic or foreign.
What’s Changed
- Under the new revenue procedure, SRE expenditures paid or incurred in domestic operations must be capitalized and **amortized over 5 years, or 15 years for expenditures related to foreign research. (irs.gov)
- Taxpayers may need to change their methods of accounting to comply. These changes are made via Form 3115, which includes both automatic and non-automatic change procedures. (irs.gov)
- There are specific transition rules: items paid or incurred before January 1, 2022, use earlier accounting; for years beginning after December 31, 2024, new amortization must be adopted. (irs.gov)
Why It Matters
- A major cash flow impact: businesses that previously deducted R&E expenses immediately will now spread deductions over several years. This changes taxable income and tax liability in early years.
- Financial reporting alignment: companies will need to adjust their internal accounting systems to reflect amortized expense over time.
- Audit risk: failure to adopt the required changes properly can trigger IRS adjustments under § 481 and § 446. (irs.gov)
Practical Steps & Examples
- Assess your R&E expenditures: Determine whether you have incurred domestic or foreign R&E after Dec 31, 2021, and especially after Dec 31, 2024.
- Example: A biotech firm in California incurs $1 million in domestic R&E in FY 2023—this must now be amortized over 5 years rather than immediately expensed.
- Review your current accounting method: If you have been deducting expenses under older standards, you may need to change method with Form 3115.
- Automatic change method may apply depending on your type of taxpayer and amounts.
- Compute § 481 adjustments: These adjustments reconcile differences from past treatment to new method, often spreading over several years.
- Update financial systems and projections: Budgeting and forecasting must account for lower deductions in early years.
- Consult tax advisor: Especially for foreign R&E or companies with complex past R&E treatment.
Case Illustration
- Domestic startup with $500,000 in SRE paid in 2024 will amortize over 5 years. Prior to change, it might have deducted the full amount in 2024. Now annual deduction becomes $100,000 (ignoring proration).
- International R&D center paying $300,000 for foreign research in 2025 gains deductions spread over 15 years—only $20,000/year decelerated.
Action Plan for 2025 & Beyond
| Task | Deadline / Timing | Responsible Party |
|---|---|---|
| Inventory all R&E / SRE expenses since 2021 | Now | Tax team/Controller |
| Decide whether automatic procedures apply | Q1 2025 or before filing | Tax accountant |
| File Form 3115 if needed | With return or penalty safe harbor in mind | Tax professional |
| Forecast cash flow accordingly | For budgeting cycles | CFO / Finance Team |
Conclusion
The shift from immediate deduction to amortization for R&E expenses under IRS § 174 and related rules is one of the most significant tax accounting developments in recent years. Companies that proactively adapt—by assessing expenses, changing accounting methods, and adjusting financial forecasts—can mitigate cash flow surprises and stay compliant.